American Society of Hirudotherapy

Cardiovascular drug highlight: hirudin

Review published in Heart disease (Hagerstown, Md.) (1999)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewClinical LiteratureDrug DevelopmentCheng-Lai A · Heart disease (Hagerstown, Md.), 1999

Abstract

Hirudin is a polypeptide of 65 to 66 amino acids derived from the saliva of the medicinal leech Hirudo medicinalis. It is the most potent naturally occurring specific inhibitor of thrombin. Through genetic engineering, recombinant forms of hirudin (r-hirudin) have been made available in sufficient quantities for therapeutic use. Because hirudin is capable of inhibiting clot-bound thrombin and fluid-phase thrombin, it has great potential for management of patients with various types of thromboembolic complications. Clinical trials with hirudin have been conducted in patients with coronary artery disease, heparin-induced thrombocytopenia, and in patients undergoing orthopedic surgery. The results of selected clinical trials in each of these areas are reviewed here. At present, most clinical benefits of r-hirudin have been demonstrated in the management of patients with heparin-induced thrombocytopenia. For this reason, lepirudin (a form of r-hirudin) has recently been approved by the United States Food and Drug Administration (FDA) for anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsCoronary Artery DiseaseHeparinHirudin TherapyHirudinsHumansThrombinThrombocytopeniaThromboembolism

Summary

This review covers the leech-derived thrombin inhibitor hirudin and its recombinant forms, summarizing clinical trials in coronary artery disease, heparin-induced thrombocytopenia and orthopedic surgery; benefits are best established for HIT, leading to FDA approval of lepirudin for that indication.

Why This Matters for Hirudotherapy

This review examines hirudin, a 65-66 amino acid polypeptide derived from the saliva of the medicinal leech Hirudo medicinalis, and surveys clinical trials of recombinant hirudin in coronary artery disease, heparin-induced thrombocytopenia, and orthopedic surgery. The abstract identifies hirudin as the most potent naturally occurring specific inhibitor of thrombin, capable of inhibiting both clot-bound and fluid-phase thrombin, and notes that lepirudin, a form of recombinant hirudin, received FDA approval for anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease. As a review, it synthesizes existing clinical evidence rather than presenting new primary data; readers should consult the underlying trial reports for quantitative outcome details.

Citation

Reference (Vancouver style)

Cheng-Lai A. Cardiovascular drug highlight: hirudin. Heart Dis. 1999;1(1):41-49. PMID: 11720603

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: March 18, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.